RTT-1

RTT-1 is a clinical-stage mRNA lipid nanoparticle (LNP) protein replacement therapy being developed by Grann Pharmaceuticals for the treatment of Rett syndrome (RTT). It is designed to compensate for the lack of functional MECP2 protein in individuals with RTT, a rare, X-linked neurodevelopmental disorder caused by mutations in the MECP2 gene. RTT-1 is currently being investigated in a clinical trial, and there is no publicly available information on its specific mechanism of action beyond its intended use as a MECP2 protein replacement via mRNA delivered by LNPs. The goal of RTT-1 is to restore functional MECP2 protein levels, which is hypothesized to ameliorate or halt disease progression. Its development pathway is similar to other mRNA-LNP-based protein replacement therapies, which have emerged as a promising approach for monogenic disorders.

Other names

Eleanor